Hill-Rom Holdings, Inc. (NYSE:HRC) stock price target increased to $66.00, released a report earlier today by Zacks Investment Research
- Updated: September 21, 2016
Stating as potential upside of 0.11%, Zacks Investment Research raised the target price of Hill-Rom Holdings, Inc. (NYSE:HRC) to $66.00
Yesterday Hill-Rom Holdings, Inc. (NYSE:HRC) traded 0.88% higher at $59.40. The company’s 50-day moving average is $58.36 and its 200-day moving average is $52.27. The last stock close price is up 14.32% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 249,493 shares of the stock were exchanged, down from an average trading volume of 544,738
Recent Performance Chart
Hill-Rom Holdings, Inc. has 52 week low of $42.99 and a 52 week high of $60.48 with a P/E ratio of 61.53 and has a market capitalization of $0.
General Company Details For Hill-Rom Holdings, Inc. (NYSE:HRC)
Hill-Rom Holdings, Inc. is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn. The North America segments sells and rents its support and near-patient technologies and services, as well as its clinical workflow solutions in the United States and Canada. The Surgical and Respiratory Care segment sells and rents its surgical and respiratory care products across the globe. Its International segment sells and rents similar products as the Company's North America segment in regions outside of the United States and Canada. Its Welch Allyn segment sells medical diagnostic equipment and a portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases across the globe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.